Physician profile
Jacquelyn Amodeo
NPI 1033705033
$1,326.82
in general payments reported to CMS, 2019-2025
12 companies · $93.50 in 2025
The $93.50 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $149 · 2022: $484 · 2023: $446 · 2024: $154 · 2025: $93.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $693.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $409.67 | 2022-2024 | |
| Glaxosmithkline, LLC. | $263.57 | 2021-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $235.69 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $94.27 | 2022-2023 | Ozempic, Rybelsus, Wegovy |
| Bausch Health US, LLC | $77.31 | 2021-2022 | |
| Exact Sciences Corporation | $67.42 | 2023-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $49.15 | 2025 | Watchman Flx |
| Althera Pharmaceuticals LLC | $48.52 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.07 | 2021 | |
| Idorsia Pharmaceuticals US INC | $26.35 | 2023 | Quviviq |
| Pfizer INC. | $14.94 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacquelyn Amodeo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.